Astellas Pharma Inc

This study tested a single dose of a new drug called ASKP1240 in 50 people who just received a kidney transplant. The goal was to check how the drug moves through the body, its safety, and how well it is tolerated. Participants were randomly assigned to receive either the drug or…

This study tested a new drug, gilteritinib, given together with standard chemotherapy for adults who were just diagnosed with acute myeloid leukemia (AML), a fast-growing blood cancer. The first part of the study looked for the safest dose of gilteritinib, and the second part che…

This study tested the drug enzalutamide in 395 men with advanced prostate cancer that had spread and was no longer controlled by standard hormone therapy. Participants had not yet received chemotherapy. The goal was to see if enzalutamide could delay the rise of PSA levels, a mar…

This study tested whether adding an experimental drug (OSI-906) to the standard maintenance drug erlotinib could help people with advanced non-small cell lung cancer (NSCLC) live longer without their cancer growing. The trial included 205 adults whose cancer had not worsened afte…

This study tested whether adding the experimental drug OSI-906 to the standard targeted therapy erlotinib (Tarceva) helps people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. 88 participants who had not received prior chemotherapy were randomly …

This study tested a medicine called fezolinetant to treat hot flashes in Japanese women going through menopause. 277 women took either the medicine or a placebo daily for up to a year. The main goal was to check the medicine's safety and how well the women tolerated it.

This study tested a medicine called fezolinetant to see if it can reduce hot flashes in Japanese women going through menopause. About 410 women took either a low dose, high dose, or a placebo pill daily for 12 weeks. The main goal was to see if the medicine lowered the number of …